90641-65-9

Usage

Uses

Used in Pharmaceutical Research:
5-Amino-1-ethyl-pyrazole-4-carboxylic acid is used as a building block for the synthesis of various biologically active compounds and potential drug candidates. Its unique structure allows for the development of new pharmaceuticals with diverse therapeutic properties.
Used in Organic Dyes and Pigments:
5-Amino-1-ethyl-pyrazole-4-carboxylic acid is also used in the development of organic dyes and pigments. Its chemical properties make it a valuable component in creating a wide range of colors and shades for various applications.
Used in Materials Science:
Due to its unique chemical properties, 5-Amino-1-ethyl-pyrazole-4-carboxylic acid has potential applications in the field of materials science. It can be utilized in the development of new materials with specific properties, such as improved stability, reactivity, or other desirable characteristics.

InChI:InChI=1/C8H13N3O2/c1-3-11-7(9)6(5-10-11)8(12)13-4-2/h5H,3-4,9H2,1-2H3

Upstream product

• 42466-67-1 ethyl (ethoxymethylene)cyanoacetate 
• 624-80-6 ethylhydrazine 
• 6629-60-3 ethylhydrazine oxalic acid salt 
• 94-05-3 ethyl (ethoxymethylene)cyanoacetate 
• 74-96-4 ethyl bromide 
• 6994-25-8 3-amino-4-pyrazolecarboxylic acid ethyl ester 
• 57338-28-0 Ethyl α-cyano<(dimethylamino)methylene>acetate 
• 35532-19-5 ethylhydrazine oxalate 

Downstream Products

• 89852-92-6 1-ethyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 
• 171084-23-4 5-Amino-6-(4-bromo-phenylamino)-1-ethyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 
• 171084-22-3 2-ethyl-N-(4-carboethoxypyrazol-3-yl)-N'-(4-bromophenyl)thiourea 
• 104440-57-5 diethyl-(1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 
• 1361961-20-7 ethyl 5-(3-benzoylthioureido)-1-ethyl-1H-pyrazole-4-carboxylate 
• 1361961-21-8 ethyl 3-(3-benzoylthioureido)-1-ethyl-1H-pyrazole-4-carboxylate 
• 1361961-24-1 2-ethyl-6-(4-fluorophenylthio)-2H-pyrazolo[3,4-d]pyrimidin-4-ol 

Relevant academic research and scientific papers

PHARMACEUTICAL COMPOUNDS

Benzodiazepine derivatives of formula (I): (I) wherein: each of R1 and R2 is independently H or halo; R3 is H, C1-C6 alkyl or -NHR8; either (i), a, c and c are all bonds, with, b,d and f absent; or b, d, and f are all bonds, with a, c, and c absent; R4 is H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; R5 is H or halo; R6 is -OR8, -NR8R9 or -R8; R7 is H or halo; each of R8 and R9 is independently H or a group selected from C1-C6 alkyl, C3-C6 cycloalkyl and 4- to 10-membered heterocyclyl, the group being unsubstituted or substituted; n is 1 or 2; and one of V, W and X is N or CH and the other two are CH; and the pharmaceutically acceptable salts thereof are inhibitors of RSV and can therefore be used to treat or prevent an RSV infection.

COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS

The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS

The present application relates to substituted fused heteroaryl and heterocyclic compounds, useful as nicotinamide adenine dinucleotide phosphate oxidase inhibitors (NADPH oxidase inhibitors), processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by NADPH oxidase. (Formula I)

BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

AZOLOPYRIDINE AND AZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are azolopyridine and azolopyrimidine compounds for treatment of JAK kinase mediated diseases, including JAK2 kinase-, JAK3 kinase- or TYK2 kinase-mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.